GeneDx (WGS) Competitors $69.38 -1.66 (-2.34%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends WGS vs. HIMS, SHC, GH, OPCH, BTSG, VCYT, SGRY, LFST, CON, and PACSShould you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Hims & Hers Health (HIMS), Sotera Health (SHC), Guardant Health (GH), Option Care Health (OPCH), BrightSpring Health Services (BTSG), Veracyte (VCYT), Surgery Partners (SGRY), LifeStance Health Group (LFST), Concentra Group Holdings Parent (CON), and PACS Group (PACS). These companies are all part of the "healthcare" industry. GeneDx vs. Hims & Hers Health Sotera Health Guardant Health Option Care Health BrightSpring Health Services Veracyte Surgery Partners LifeStance Health Group Concentra Group Holdings Parent PACS Group Hims & Hers Health (NYSE:HIMS) and GeneDx (NASDAQ:WGS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability. Which has more risk & volatility, HIMS or WGS? Hims & Hers Health has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Does the media prefer HIMS or WGS? In the previous week, Hims & Hers Health had 15 more articles in the media than GeneDx. MarketBeat recorded 32 mentions for Hims & Hers Health and 17 mentions for GeneDx. GeneDx's average media sentiment score of 0.44 beat Hims & Hers Health's score of 0.26 indicating that GeneDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 9 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral GeneDx 8 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community favor HIMS or WGS? Hims & Hers Health received 27 more outperform votes than GeneDx when rated by MarketBeat users. However, 47.62% of users gave GeneDx an outperform vote while only 37.37% of users gave Hims & Hers Health an outperform vote. CompanyUnderperformOutperformHims & Hers HealthOutperform Votes3737.37% Underperform Votes6262.63% GeneDxOutperform Votes1047.62% Underperform Votes1152.38% Do insiders and institutionals have more ownership in HIMS or WGS? 63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 17.7% of Hims & Hers Health shares are held by company insiders. Comparatively, 27.3% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is HIMS or WGS more profitable? Hims & Hers Health has a net margin of 8.19% compared to GeneDx's net margin of -31.25%. Hims & Hers Health's return on equity of 10.97% beat GeneDx's return on equity.Company Net Margins Return on Equity Return on Assets Hims & Hers Health8.19% 10.97% 8.29% GeneDx -31.25%-13.35%-6.91% Do analysts recommend HIMS or WGS? Hims & Hers Health presently has a consensus target price of $20.71, indicating a potential downside of 4.98%. GeneDx has a consensus target price of $59.33, indicating a potential downside of 14.48%. Given Hims & Hers Health's higher probable upside, analysts clearly believe Hims & Hers Health is more favorable than GeneDx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hims & Hers Health 1 Sell rating(s) 8 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.38GeneDx 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher earnings & valuation, HIMS or WGS? Hims & Hers Health has higher revenue and earnings than GeneDx. GeneDx is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHims & Hers Health$1.24B3.83-$23.55M$0.4449.55GeneDx$267.23M7.13-$175.77M-$3.11-22.31 SummaryHims & Hers Health beats GeneDx on 12 of the 18 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get GeneDx News Delivered to You Automatically Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WGS vs. The Competition Export to ExcelMetricGeneDxHealth services IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.91B$617.16M$5.03B$8.81BDividend YieldN/A1.96%5.16%4.06%P/E Ratio-22.3137.32135.4117.82Price / Sales7.133.911,160.9774.56Price / CashN/A25.4733.5332.53Price / Book7.902.904.674.68Net Income-$175.77M-$10.72M$119.07M$226.08M7 Day Performance-5.90%-1.16%-1.83%-1.04%1 Month Performance19.23%-2.51%-3.60%1.04%1 Year Performance4,855.71%387.32%31.66%26.28% GeneDx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WGSGeneDx1.1554 of 5 stars$69.38-2.3%$59.33-14.5%+4,891.4%$1.91B$267.23M-22.311,200Insider TradeNews CoverageHIMSHims & Hers Health3.5685 of 5 stars$21.80-7.4%$20.71-5.0%+181.8%$5.14B$872M49.551,046Analyst ForecastInsider TradeSHCSotera Health3.662 of 5 stars$13.21-2.9%$16.50+24.9%-5.2%$3.85B$1.05B52.843,000High Trading VolumeGHGuardant Health4.2798 of 5 stars$30.68flat$40.60+32.3%+28.4%$3.79B$563.95M-7.241,779OPCHOption Care Health4.9777 of 5 stars$21.88+0.3%$30.83+40.9%-26.3%$3.72B$4.30B18.397,802Positive NewsBTSGBrightSpring Health Services2.9593 of 5 stars$18.79+0.8%$16.79-10.6%N/A$3.27B$10.59B-72.2735,000Positive NewsVCYTVeracyte4.1281 of 5 stars$39.20+0.1%$41.25+5.2%+50.5%$3.03B$361.05M-261.33790Analyst ForecastSGRYSurgery Partners3.0975 of 5 stars$22.51-1.1%$38.71+72.0%-29.9%$2.89B$2.74B0.0013,500Analyst ForecastLFSTLifeStance Health Group1.7828 of 5 stars$7.22-0.3%$8.50+17.7%+16.5%$2.76B$1.21B-27.779,325CONConcentra Group Holdings ParentN/A$21.27+4.9%$28.50+34.0%N/A$2.71B$1.84B0.0011,000Gap UpHigh Trading VolumePACSPACS Group4.0685 of 5 stars$17.25+0.9%$39.88+131.2%N/A$2.61B$3.11B0.0032,433Analyst Forecast Related Companies and Tools Related Companies HIMS Competitors SHC Competitors GH Competitors OPCH Competitors BTSG Competitors VCYT Competitors SGRY Competitors LFST Competitors CON Competitors PACS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:WGS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free WGS Stock Alerts